SynthesisEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025
Prediction of ventricular arrhythmias and sudden cardiac death by quantification and location of late gadolinium enhancement on cardiac magnetic resonance: a systematic review and meta-analysis.
Synthesis in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Arrhythmogenic right ventricular cardiomyopathy with left ventricular noncompaction: A phenotypic overlap with high arrhythmic risk.HeartRhythm case reports · 2026Article
- Refining risk stratification for primary prevention ICD therapy: Insights from cardiac MRI in the DO-IT registry.Heart rhythm O2 · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIn non-ischaemic cardiomyopathy (NICM), late gadolinium enhancement (LGE) detected by cardiovascular magnetic resonance is related to ventricular arrhythmia (VA) and sudden cardiac death (SCD) risk. The incremental prognostic value of quantifying LGE volume or mass beyond its mere presence, however, remains unresolved. The aim was to evaluate whether LGE quantification improves the prediction of SCD. METHODS AND
resultsPubMed, Embase, and Web of Science were searched on 20 November 2024 for observational studies that related quantified LGE burden to ventricular arrhythmia (VA)/SCD in NICM. Forty-one studies met prespecified criteria. Hazard ratios (HRs) were pooled with random-effects models, and quantification information was depicted in figures. Presence of any LGE was associated with a three-fold increase in VA/SCD risk (pooled HR 3.31, 95% confidence interval: 2.58-4.24). Beyond this binary marker, every additional 1% (or 1 g) of LGE was associated with a 12% relative risk increase (range 10-20%), independent of left ventricular ejection fraction and consistent across eight semi-automated thresholding techniques. This included 2-6 standard deviations above the reference myocardium and the full-width half-maximum method. Additionally, results were prone to substantial methodological heterogeneity (τ² = 1.49) and small-study bias. Once the presence of LGE was accounted for, scar quantification and location conferred minimal additional prognostic value.
conclusionQuantitative LGE assessment provides little incremental prognostic utility over dichotomous LGE detection. Consensus imaging standards and prospective validation are requisite before LGE burden can guide primary implantable cardioverter defibrillator allocation in NICM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.